A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutation and a residual function mutation
Titel:
A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutation and a residual function mutation
Auteur:
Davies, Jane C. Sermet-Gaudelus, Isabelle Naehrlich, Lutz Harris, R. Scott Campbell, Daniel Ahluwalia, Neil Short, Christopher Haseltine, Eric Panorchan, Paul Saunders, Clare Owen, Caroline A. Wainwright, Claire E.